• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Calyxt Completes One-for-Ten Reverse Stock Split

    4/24/23 4:35:00 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials
    Get the next $CLXT alert in real time by email

    ROSEVILLE, Minn., April 24, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company") today announced that it has completed the previously announced reverse stock split of Calyxt's common stock, par value $0.0001 per share ("Common Stock"), at a ratio of 1-for-10. The reverse stock split was previously approved by the Company's stockholders at the annual meeting of shareholders on June 1, 2022.

    Calyxt filed an amendment to its amended and restated certificate of incorporation to effectuate the reverse stock split as of 4:30 p.m. Eastern time on April 24, 2023 (the "effective date") and the Common Stock will begin trading on an adjusted basis giving effect to the reverse stock split when the Nasdaq Capital Market opens on April 25, 2023. The Common Stock will continue trading on the Nasdaq Capital Market under the symbol "CLXT," but will trade under a new CUSIP number (13173L206).

    As a result of the reverse stock split, every ten shares of Common Stock issued and outstanding or held as treasury shares as of the effective date were automatically combined into one share of Common Stock. This reduced the number of outstanding shares of Common Stock from approximately 49.7 million to approximately 5.0 million. The reverse stock split had no effect on the number of shares of Common Stock authorized for issuance or on the par value of the Common Stock.

    Outstanding Calyxt equity-based awards under Calyxt's benefit plans were proportionately adjusted. No fractional shares were issued in connection with the reverse stock split and any fractional shares resulting from the reverse stock split were rounded up to the nearest whole share.

    The Company's transfer agent, Broadridge Corporate Issuer Solutions, Inc., is acting as exchange agent for the reverse stock split. Registered stockholders holding pre-split shares of Common Stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning Common Stock via a broker, bank, custodian or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker's particular processes, and will not be required to take any action in connection with the reverse stock split. Such beneficial holders are encouraged to contact their broker, bank or custodian with any procedural questions.

    Additional information concerning the reverse stock split can be found in Calyxt's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on April 19, 2022.

    About Calyxt

    Calyxt (NASDAQ:CLXT) is a plant-based synthetic biology company. Calyxt leverages its proprietary PlantSpring™ technology platform and Plant Cell Matrix™ structures to engineer plant metabolism to produce innovative high value plant-based chemistries for use in customers' materials and products. As plant-based solutions, Calyxt's synthetic biology products can be used in helping customers meet their sustainability targets and financial goals. Calyxt's diversified offerings are primarily delivered through its proprietary BioFactory production system. For more information, visit www.calyxt.com.

    PlantSpring, Plant Cell Matrix, PCM, BioFactory, and the Calyxt logo are trademarks of Calyxt, Inc. Any other trademarks belong to their respective owners.

    Contact

    Bill Koschak

    [email protected] 

    651-425-1754

    Logo (PRNewsfoto/Calyxt, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/calyxt-completes-one-for-ten-reverse-stock-split-301805714.html

    SOURCE Calyxt, Inc.

    Get the next $CLXT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLXT

    DatePrice TargetRatingAnalyst
    3/4/2022$6.00 → $4.00Buy
    Canaccord Genuity
    11/2/2021$10.00Buy
    ROTH Capital
    More analyst ratings

    $CLXT
    SEC Filings

    View All

    Calyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cibus, Inc. (0001705843) (Filer)

    1/9/24 4:47:04 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Cibus, Inc. (0001705843) (Filer)

    1/2/24 7:15:59 AM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    SEC Form 424B5 filed by Calyxt Inc.

    424B5 - Cibus, Inc. (0001705843) (Filer)

    1/2/24 7:07:41 AM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    $CLXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Riggs Rory B converted options into 1,500,000 shares and acquired 1,505,967 units of Class B Common Stock, increasing direct ownership by 128% to 3,103,788 units (SEC Form 4)

    4 - Cibus, Inc. (0001705843) (Issuer)

    1/3/24 7:08:08 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

    4 - Cibus, Inc. (0001705843) (Issuer)

    12/14/23 5:10:06 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    SEC Form 3: New insider Collins James C. Jr. claimed no ownership of stock in the company

    3 - Cibus, Inc. (0001705843) (Issuer)

    9/25/23 4:49:52 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    $CLXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

    4 - Cibus, Inc. (0001705843) (Issuer)

    12/14/23 5:10:06 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    $CLXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity reiterated coverage on Calyxt with a new price target

    Canaccord Genuity reiterated coverage of Calyxt with a rating of Buy and set a new price target of $4.00 from $6.00 previously

    3/4/22 8:44:27 AM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    ROTH Capital initiated coverage on Calyxt with a new price target

    ROTH Capital initiated coverage of Calyxt with a rating of Buy and set a new price target of $10.00

    11/2/21 8:38:36 AM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    Canaccord Genuity resumed coverage on Calyxt with a new price target

    Canaccord Genuity resumed coverage of Calyxt with a rating of Buy and set a new price target of $16.00

    2/22/21 7:29:33 AM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    $CLXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

    EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

    1/28/25 8:00:00 AM ET
    $CBUS
    $CLLS
    $MGX
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calyxt Announces Stockholder Approval of Merger With Cibus

    -- Calyxt Announces 1-for-5 Reverse Stock Split of Common Stock -- ROSEVILLE, Minn., May 19, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company") today announced the results of the special meeting of its stockholders held on May 18, 2023. At the special meeting, Calyxt's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Class A common stock and Class B common stock to the equity holders of Cibus Global, LLC ("Cibus") as part of the previously announced proposed merger with Cibus. The closing of the merger is anticipated to take place on or around Wednesday, May 31, 2023, subject to the satisfaction of the remainin

    5/19/23 4:01:00 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update

    —Proposed merger with Cibus Global Expected to Close in Q2 2023— —1-for-10 reverse stock split executed— —Current customer projects under development are on track— —Evologic Technologies completed initial phase of project to scale production of Calyxt's Plant Cell Matrix™ and BioFactoryTM technologies— ROSEVILLE, Minn., May 1, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023. Merger Agreement with Cibus On January 17, 2023, Calyxt announced it had entered into a definitive merger agreement (the Merger Agreement) with Cibus Global, LLC (Cibus), a leader in precis

    5/1/23 4:01:00 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    $CLXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Calyxt Inc. (Amendment)

    SC 13G/A - Cibus, Inc. (0001705843) (Subject)

    2/9/24 8:50:20 AM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by Calyxt Inc.

    SC 13G - Cibus, Inc. (0001705843) (Subject)

    7/10/23 10:20:11 AM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    SEC Form SC 13D filed by Calyxt Inc.

    SC 13D - Cibus, Inc. (0001705843) (Subject)

    6/12/23 5:28:58 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    $CLXT
    Financials

    Live finance-specific insights

    View All

    Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    —Successfully produced squalene, an important ingredient for personal care products and vaccine adjuvants— —Continued to progress customer acquisition activities, including evaluating an incremental 37 customer chemistries for development using PlantSpring™ and BioFactory™ technologies— —Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell Matrix™ technology platform— —Continuing board-level evaluation of a full range of potential strategic alternatives to maximize shareholder value— —Selected for membership to BioMADE, a Department of Defense-sponsored initiative that brings together industrial, academic and non-profit entities to advance US

    11/3/22 4:01:00 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    Calyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time

    ROSEVILLE, Minn., Oct. 27, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, November 3, 2022, at 4:30 p.m. ET to discuss results for the third quarter ended September 30, 2022. A press release detailing these results will be issued prior to the call. President and Chief Executive Officer, Michael A. Carr, and Chief Financial Officer, Bill Koschak, will host the conference call. The conference call will be webcast and can be accessed via the investor relations section of the Company's

    10/27/22 7:00:00 AM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    Calyxt Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    Evaluated nine new customer demand-driven plant-based chemistries in the quarter, bringing cumulative chemistries evaluated for development to 95, of these 31 meet Calyxt's target profile and several are the subject of term sheet discussions Engineering solution for a high-value molecule planned to be delivered in early 2023 to a large global consumer packaged goods company Progressing discussions with multiple potential infrastructure partners who would produce chemistries in various sizes of bioreactors from pilot to commercial scale Evaluating term sheets for technology licensing and for licensing of traits Management to host conference call and webcast today at 4:30 p.m. ET ROSEVILLE, Mi

    8/4/22 4:01:00 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    $CLXT
    Leadership Updates

    Live Leadership Updates

    View All

    Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

    EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

    1/28/25 8:00:00 AM ET
    $CBUS
    $CLLS
    $MGX
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calyxt Names IBM's Global Chief Artificial Intelligence Officer, Dr. Seth Dobrin, to Scientific Advisory Board

    ROSEVILLE, Minn., Oct. 12, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced the appointment of Seth Dobrin, Ph.D., to the Company's Scientific Advisory Board (SAB). Dr. Dobrin is the Global Chief Artificial Intelligence (AI) Officer at IBM and brings extensive leadership experience and a track record of transforming companies through data and AI. "We warmly welcome Seth to our Scientific Advisory Board. Seth is a visionary whose deep experience bringing AI-based business solutions to major global corporations will be invaluable as we continue to develop and augment the AI and machine learning (AIML) capabilities of our PlantSprin

    10/12/21 7:00:00 AM ET
    $CLXT
    Agricultural Chemicals
    Industrials

    Calyxt Appoints Michael A. Carr as Chief Executive Officer

    ROSEVILLE, Minn., July 15, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based biotechnology platform company, today announced the appointment of Michael A. Carr as President and Chief Executive Officer, effective July 27, 2021. Mr. Carr will also serve as a member of Calyxt's Board of Directors. Mr. Carr was most recently the Vice President of M&A, Strategy, and Innovation at Darling Ingredients, Inc., a global developer and producer of sustainable natural ingredients and renewable energy. "Michael's operational, financial, and investment experience, paired with his diverse knowledge across industries including health, nutrients, bioenergy and services will be integral as we adva

    7/15/21 4:01:00 PM ET
    $CLXT
    Agricultural Chemicals
    Industrials